Fexmid Tablet
NDC 64980-705
Product Information
Fexmid (cyclobenzaprine hydrochloride) is a ANDA-approved product labeled by Rising Pharma Holdings, Inc.. Cyclobenzaprine is used short-term to treat muscle spasms. It is supplied as a white tablet for oral administration. This product entry covers the primary NDC 64980-705 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
C7;5;GR
Code Structure Chart
Product Details
What is NDC 64980-705?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CYCLOBENZAPRINE HYDROCHLORIDE (UNII: 0VE05JYS2P)
- CYCLOBENZAPRINE (UNII: 69O5WQQ5TI) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- MICROCRYSTALLINE CELLULOSE (UNII: OP1R32D61U)
- ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)
- STARCH, CORN (UNII: O8232NY3SJ)
- CROSPOVIDONE (UNII: 2S7830E561)
- SILICON DIOXIDE (UNII: ETJ7Z6XBU4)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- HYPROMELLOSE 2910 (6 MPA.S) (UNII: 0WZ8WG20P6)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- POLYETHYLENE GLYCOL 8000 (UNII: Q662QK8M3B)
- TALC (UNII: 7SEV7J4R1U)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 828299 - cyclobenzaprine HCl 7.5 MG Oral Tablet
- RxCUI: 828299 - cyclobenzaprine hydrochloride 7.5 MG Oral Tablet
- RxCUI: 828301 - Fexmid 7.5 MG Oral Tablet
- RxCUI: 828301 - cyclobenzaprine hydrochloride 7.5 MG Oral Tablet [Fexmid]
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.